| [1] |
Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update[J]. World J Urol, 2020, 38(8): 1895-1904. DOI: 10.1007/s00345-019-02984-4.
|
| [2] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
| [3] |
Devlies W, de Jong JJ, Hofmann F, et al. The diagnostic accuracy of cystoscopy for detecting bladder cancer in adults presenting with haematuria: a systematic review from the European association of urology guidelines office[J]. Eur Urol Focus, 2024, 10(1): 115-122. DOI: 10.1016/j.euf.2023.08.002.
|
| [4] |
Guldhammer CS, Vásquez JL, Kristensen VM, et al. Cystoscopy accuracy in detecting bladder tumors: a prospective video-confirmed study[J]. Cancers, 2023, 16(1): 160. DOI: 10.3390/cancers16010160.
|
| [5] |
|
| [6] |
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013.
|
| [7] |
Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer[J]. Nat Rev Urol, 2013, 10(6): 327-335. DOI: 10.1038/nrurol.2013.89.
|
| [8] |
Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer[J]. J Clin Invest, 2020, 130(12): 6278-6289. DOI: 10.1172/JCI139597.
|
| [9] |
Wang P, Shi Y, Zhang J, et al. UCseek: ultrasensitive early detection and recurrence monitoring of urothelial carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment DNA[J]. EBioMedicine, 2023, 89: 104437. DOI: 10.1016/j.ebiom.2023.104437.
|
| [10] |
Ruan W, Chen X, Huang M, et al. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer[J]. Clin Epigenetics, 2021, 13(1): 91. DOI: 10.1186/s13148-021-01073-x.
|
| [11] |
Feber A, Dhami P, Dong L, et al. UroMark-a urinary biomarker assay for the detection of bladder cancer[J]. Clin Epigenetics, 2017, 9: 8. DOI: 10.1186/s13148-016-0303-5.
|
| [12] |
van Kessel KE, Beukers W, Lurkin I, et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy[J]. J Urol, 2017, 197(3 Pt 1): 590-595. DOI: 10.1016/j.juro.2016.09.118.
|
| [13] |
D'Andrea D, Soria F, Zehetmayer S, et al. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer[J]. BJU Int, 2019, 123(6): 959-967. DOI: 10.1111/bju.14673.
|
| [14] |
Piatti P, Chew YC, Suwoto M, et al. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples[J]. Clin Epigenetics, 2021, 13(1): 84. DOI: 10.1186/s13148-021-01029-1.
|
| [15] |
Xiao Y, Ju L, Qian K, et al. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study[J]. Clin Transl Med, 2022, 12(8): e1008. DOI: 10.1002/ctm2.1008.
|
| [16] |
Casadio V, Calistri D, Tebaldi M, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data[J]. Urol Oncol, 2013, 31(8): 1744-1750. DOI: 10.1016/j.urolonc.2012.07.013.
|
| [17] |
Ma ML, Zhang WZ, Jiang P, et al. Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnostics[J]. Med, 2025, 6(7): 100646. DOI: 10.1016/j.medj.2025.100646.
|
| [18] |
Avogbe PH, Manel A, Vian E, et al. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer[J]. EBioMedicine, 2019, 44: 431-438. DOI: 10.1016/j.ebiom.2019.05.004.
|
| [19] |
Zvereva M, Hosen MI, Forey N, et al. Simplex droplet digital PCR assays for the detection of TERT promoter mutations in urine samples for the non-invasive diagnosis of urothelial cancer[J]. Methods Mol Biol, 2023, 2684: 213-228. DOI: 10.1007/978-1-0716-3291-8_13.
|
| [20] |
Rabien A, Rong D, Rabenhorst S, et al. Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer[J]. Sci Rep, 2024, 14(1): 30617. DOI: 10.1038/s41598-024-83976-2.
|
| [21] |
Hayashi Y, Fujita K, Matsuzaki K, et al. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma[J]. Cancer Sci, 2019, 110(5): 1771-1779. DOI: 10.1111/cas.14000.
|
| [22] |
Tan D, Jiang W, Hu R, et al. Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR[J]. Cancer Med, 2023, 12(10): 11503-11512. DOI: 10.1002/cam4.5879.
|
| [23] |
Jain M, Tivtikyan A, Kamalov D, et al. Development of a sensitive digital droplet PCR screening assay for the detection of GPR126 non-coding mutations in bladder cancer urine liquid biopsies[J]. Biomedicines, 2023, 11(2): 495. DOI: 10.3390/biomedicines11020495.
|
| [24] |
Liao Y, Tang H, Wang M, et al. The potential diagnosis role of TP53 mutation in advanced bladder cancer: a meta-analysis[J]. J Clin Lab Anal, 2021, 35(5): e23765. DOI: 10.1002/jcla.23765.
|
| [25] |
Hamada A, Kita Y, Sakatani T, et al. PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations[J]. Oncogene, 2025, 44(19): 1336-1349. DOI: 10.1038/s41388-025-03311-5.
|
| [26] |
Lin YC, Chen TH, Huang YM, et al. Involvement of microRNA in solid cancer: role and regulatory mechanisms[J]. Biomedicines, 2021, 9(4): 343. DOI: 10.3390/biomedicines9040343.
|
| [27] |
Chattopadhyay A, Kural S, Verma A, et al. Urinary miRNAs in bladder cancer[J]. Clin Chim Acta, 2025, 567: 120113. DOI: 10.1016/j.cca.2024.120113.
|
| [28] |
Erdmann K, Salomo K, Klimova A, et al. Urinary microRNAs as potential markers for non-invasive diagnosis of bladder cancer[J]. Int J Mol Sci, 2020, 21(11): 3814. DOI: 10.3390/ijms21113814.
|
| [29] |
Wang P, Wei X, Qu X, et al. Potential clinical application of microRNAs in bladder cancer[J]. J Biomed Res, 2024, 38(4): 289-306. DOI: 10.7555/JBR.37.20230245.
|
| [30] |
Yu X, Wang R, Han C, et al. A panel of urinary long non-coding RNAs differentiate bladder cancer from urocystitis[J]. J Cancer, 2020, 11(4): 781-787. DOI: 10.7150/jca.37006.
|
| [31] |
Bian B, Li L, Ke X, et al. Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing[J]. Front Oncol, 2022, 12: 976329. DOI: 10.3389/fonc.2022.976329.
|
| [32] |
Gao Y, Zhang X, Wang X, et al. The clinical value of rapidly detecting urinary exosomal lncRNA RMRP in bladder cancer with an RT-RAA-CRISPR/Cas12a method[J]. Clin Chim Acta, 2024, 562: 119855. DOI: 10.1016/j.cca.2024.119855.
|
| [33] |
Li J, Zhao L, Li L, et al. Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer based on microarray differential expression profiling[J]. Int J Biol Markers, 2025, 40(1): 24-34. DOI: 10.1177/03936155251317551.
|